Regeneron’s LIBTAYO Working in South Central Missouri

Apr 14, 2019 | Cancer, CSCC, Immunotherapy, LIBTAYO, Oncology

Regeneron’s Cemiplimab-rwlc (LIBTAYO) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who candidates for curative surgery or curative radiation are not. LIBTAYO is the first and only approved treatment for patients with advanced CSCC. As reported by the FDA, during extensive clinical trials 47.2 % of CSCC patients experienced a reduction in their tumors based on LIBTAYO treatment.

The Mt. Grove News Journal in Missouri reported the immunotherapy has worked wonders for a local man who battled with the advanced skin cancer when surgery was no longer an option. Dale Biggs knew where his cancer came from as he spent years working in the outdoors in the sun. He developed CSCC and ultimate ran out of options. Despite known side effects, Biggs decided to move forward with the powerful immunotherapy.  By the third month his tumors were no longer visible!  Follow the link to learn more about Dale Biggs, CSCC and LIBTAYO.

0 Comments

Pin It on Pinterest